Pharmaceutical firm Teva has received FDA approval for the Abbreviated New Drug Application (ANDA) to market Tri-Lo Sprintec, a generic version of Ortho McNeil Janssen's oral contraceptive, Ortho Tri-Cyclen Lo.
Teva has been awarded a 180-day period of marketing, as it has filed the first ANDA containing a paragraph IV certification for this product.
Teva is currently involved in patent litigation concerning this product in the US District Court for the District of New Jersey. A trial date has not been set yet.
Teva develops, manufactures and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients. The company also manufactures animal health pharmaceutical products.
No comments:
Post a Comment